Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety

Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety

Abstract Background Epidermal growth factor receptor (EGFR) is a target for cancer therapy as it is overexpressed in a wide variety of cancers. Therapeutic antibodies that bind EGFR are being evaluated in clinical trials as imaging agents for positron emission tomography and image-guided surgery. Ho...

Full description

Bibliographic Details
Main Authors: Wendy Bernhard, Kris Barreto, Ayman El-Sayed, Carolina Gonzalez, Raja Solomon Viswas, Darien Toledo, Angel Casaco, John DeCoteau, Humphrey Fonge, Clarence Ronald Geyer
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Cancer
Subjects:
Nimotuzumab
EGFR
Near-infrared fluorescence imaging
IRDye800CW
Image-guided surgery
Investigator’s brochure
Online Access:https://doi.org/10.1186/s12885-021-08003-3

Internet

https://doi.org/10.1186/s12885-021-08003-3

Similar Items